Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Use of mesenchymal stem cells for cutaneous repair and skin substitute elaboration.

Laverdet B., Micallef L., Lebreton C., Mollard J., Lataillade JJ., Coulomb B.

Clinical Trial on Chronic Wound, published in Pathol Biol (Paris) (2014) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Pathol Biol (Paris) (2014)
Country
France
Reported sample size
—
Source database
PubMed
PMID
24661975
DOI
10.1016/j.patbio.2014.01.002

Abstract (original English)

Human mesenchymal stem cells (MSCs) are a heterogeneous population of fibroblast-like cells, which are present in different locations, including bone marrow, adipose tissue, extra-foetal tissues, gingiva and dermis. MSCs, which present multipotency capacities, important expansive potential and immunotolerance properties, remain an attractive tool for tissue repair and regenerative medicine. Currently, several studies and clinical trials highlight the use of MSCs in cutaneous repair underlining that their effects are essentially due to the numerous factors that they release. MSCs are also used in skin substitute development. In this study, we will first discuss the different sources of MSCs actually available. We will then present results showing that bone marrow-derived MSCs prepared according to Good Manufacturing Practices and included in a dermal equivalent are able to promote appropriate epidermis growth and differentiation. These data demonstrate that bone marrow-derived MSCs represent a satisfactory alternative to dermal fibroblasts in order to develop skin substitute. In addition, MSCs could provide a useful alternative to sustain epidermis development and to promote wound healing.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Cell DifferentiationCells, CulturedDermisEpidermal CellsFibroblastsHumansMatrix MetalloproteinasesMesenchymal Stem Cell TransplantationMesenchymal Stem CellsOrgan Specificity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research